Personalis (NASDAQ:PSNL) Short Interest Down 6.1% in June

Personalis (NASDAQ:PSNL) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 841,100 shares, a decline of 6.1% from the June 15th total of 895,500 shares. Approximately 5.3% of the company’s stock are sold short. Based on an average trading volume of 313,200 shares, the short-interest ratio is currently 2.7 days.

In other news, major shareholder Lightspeed Venture Partners Se purchased 77,797 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was acquired at an average price of $12.98 per share, with a total value of $1,009,805.06. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 8.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its stake in shares of Personalis by 110.9% in the fourth quarter. Victory Capital Management Inc. now owns 3,043 shares of the company’s stock valued at $33,000 after buying an additional 1,600 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of Personalis by 432.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,511 shares of the company’s stock worth $44,000 after acquiring an additional 4,476 shares during the period. Deutsche Bank AG grew its holdings in shares of Personalis by 95.5% during the 1st quarter. Deutsche Bank AG now owns 6,081 shares of the company’s stock worth $49,000 after purchasing an additional 2,971 shares in the last quarter. Barclays PLC increased its position in shares of Personalis by 105.7% during the fourth quarter. Barclays PLC now owns 9,031 shares of the company’s stock valued at $98,000 after purchasing an additional 4,640 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Personalis during the first quarter valued at approximately $87,000. 60.92% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on PSNL shares. Oppenheimer began coverage on Personalis in a research report on Wednesday, June 24th. They issued a “buy” rating and a $24.00 price target for the company. BidaskClub upgraded Personalis from a “buy” rating to a “strong-buy” rating in a report on Friday. ValuEngine upgraded Personalis from a “hold” rating to a “buy” rating in a report on Friday, March 13th. Zacks Investment Research upgraded shares of Personalis from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Personalis from $13.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $20.80.

PSNL opened at $14.99 on Friday. The business has a 50 day moving average of $12.93 and a 200-day moving average of $10.38. Personalis has a 1-year low of $4.27 and a 1-year high of $25.64.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.03). Personalis had a negative net margin of 40.60% and a negative return on equity of 26.28%. The company had revenue of $19.16 million for the quarter, compared to analyst estimates of $16.80 million. As a group, sell-side analysts predict that Personalis will post -1.21 EPS for the current year.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers.

See Also: CD Ladder

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with's FREE daily email newsletter.